Fibromyalgia and bipolar disorder: Emerging epidemiological associations and shared pathophysiology

Current Molecular Medicine

Volumn 16, Issue 2, 2016, Pages 119-136

  Bortolato, B ^a   Berk, M ^b,c   Maes, M ^b   McIntyre, R S ^d,e   Carvalho, A F ^f  

^a Department of Mental Health   (Italy)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Bipolar disorder; Brain derived neurotrophic factor; Fibromyalgia; Hypothalamic pituitary adrenal axis; Inflammation; Neuroimaging; Neurology; Oxidative stress; Pathophysiology; Psychiatry

Indexed keywords

25 HYDROXYVITAMIN D; ALPHA 1 ANTITRYPSIN; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CATECHOL METHYLTRANSFERASE; DULOXETINE; GLUCOCORTICOID RECEPTOR; GLUTAMATE RECEPTOR; GLYCOPROTEIN GP 130; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MELATONIN; MILNACIPRAN; MONOCYTE CHEMOTACTIC PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE SYNTHASE; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TUMOR NECROSIS FACTOR ALPHA; VENLAFAXINE;

ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR DISORDER; COMORBIDITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DORSOLATERAL PREFRONTAL CORTEX; DORSOMEDIAL PREFRONTAL CORTEX; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DEFICIENCY; MAJOR DEPRESSION; MOOD DISORDER QUESTIONNAIRE; NERVE CELL PLASTICITY; NITROSATIVE STRESS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PAIN ASSESSMENT; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW (TOPIC); VENTROLATERAL PREFRONTAL CORTEX; VENTROMEDIAL PREFRONTAL CORTEX; COMPLICATION; IMMUNOLOGY; NEUROIMAGING; NEUROSECRETION; OXIDATIVE STRESS; PATHOLOGY;

BIPOLAR DISORDER; FIBROMYALGIA; HUMANS; NEUROIMAGING; NEURONAL PLASTICITY; NEUROSECRETORY SYSTEMS; OXIDATIVE STRESS;

EID: 84958965630     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524016666160126144027     Document Type: Article

References (244)

1. Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014; 311(15): 1547-55.
2. Wolfe F, Walitt B. Culture, science and the changing nature of fibromyalgia. Nat Rev Rheumatol 2013; 9(12): 751-5.
3. Bradley LA. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry 2008; 69 Suppl 2: 6-13.
4. Arnold LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther 2006; 8(4): 212.
5. Fietta P, Fietta P, Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed 2007; 78(2): 88-95.
6. Ohayon MM. Specific characteristics of the pain/depression association in the general population. J Clin Psychiatry 2004; 65 Suppl 12: 5-9.
7. Aguglia A, Salvi V, Maina G, Rossetto I, Aguglia E. Fibromyalgia syndrome and depressive symptoms: comorbidity and clinical correlates. J Affect Disord 2011; 128(3): 262-6.
8. Hudson JI, Goldenberg DL, Pope HG, Jr., Keck PE, Jr., Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992; 92(4): 363-7.
9. Maletic V, Raison CL. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci (Landmark Ed) 2009; 14: 5291-338.
10. Goldstein BI, Houck PR, Karp JF. Factors associated with pain interference in an epidemiologic sample of adults with bipolar I disorder. J Affect Disord 2009; 117(3): 151-6.
11. Nicholl BI, Mackay D, Cullen B, et al. Chronic multisite pain in major depression and bipolar disorder: cross-sectional study of 149,611 participants in UK Biobank. BMC Psychiatry 2014; 14(1): 350.
12. Miller CJ, Abraham KM, Bajor LA, et al. Quality of life among patients with bipolar disorder in primary care versus community mental health settings. J Affect Disord 2013; 146(1): 100-5.
13. Failde I, Duenas M, Aguera-Ortiz L, Cervilla JA, Gonzalez-Pinto A, Mico JA. Factors associated with chronic pain in patients with bipolar depression: a cross-sectional study. BMC Psychiatry 2013; 13: 112.
14. Stubbs B, Eggermont L, Mitchell AJ, et al. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis. Acta Psychiatr Scand 2015; 131(2): 75-88.
15. Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006; 67(8): 1219-25.
16. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68(3): 241-51.
17. Korszun A. Sleep and circadian rhythm disorders in fibromyalgia. Curr Rheumatol Rep 2000; 2(2): 124-30.
18. Gonzalez R. The relationship between bipolar disorder and biological rhythms. J Clin Psychiatry 2014; 75(4): e323-31.
19. Bourne C, Aydemir O, Balanza-Martinez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data metaanalysis. Acta Psychiatr Scand 2013; 128(3): 149-62.
20. Shelton RC, Reddy R. Adjunctive use of modafinil in bipolar patients: just another stimulant or not? Curr Psychiatry Rep 2008; 10(6): 520-4.
21. Vincent A, Benzo RP, Whipple MO, McAllister SJ, Erwin PJ, Saligan LN. Beyond pain in fibromyalgia: insights into the symptom of fatigue. Arthritis Res Ther 2013; 15(6): 221.
22. Brietzke E, Mansur RB, Soczynska J, Powell AM, McIntyre RS. A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39(1): 1-8.
23. Lyon P, Cohen M, Quintner J. An evolutionary stressresponse hypothesis for chronic widespread pain (fibromyalgia syndrome). Pain Med 2011; 12(8): 1167-78.
24. Sharma V, Barrett C. Tryptophan for treatment of rapidcycling bipolar disorder comorbid with fibromyalgia. Can J Psychiatry 2001; 46(5): 452-3.
25. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003; 5(6): 421-33.
26. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33(2): 160-72.
27. Haviland MG, Banta JE, Przekop P. Fibromyalgia: prevalence, course, and co-morbidities in hospitalized patients in the United States, 1999-2007. Clin Exp Rheumatol 2011; 29(6 Suppl 69): S79-87.
28. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011; 38(6): 1113-22.
29. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 2013; 17(8): 356.
30. White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999; 26(7): 1570-6.
31. Topbas M, Cakirbay H, Gulec H, Akgol E, Ak I, Can G. The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand J Rheumatol 2005; 34(2): 140-4.
32. Collado A, Gomez E, Coscolla R, et al. Work, family and social environment in patients with Fibromyalgia in Spain: an epidemiological study: EPIFFAC study. BMC Health Serv Res 2014; 14(1): 513.
33. Wolfe F, Michaud K, Li T, Katz RS. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol 2010; 37(2): 305-15.
34. Schur EA, Afari N, Furberg H, et al. Feeling bad in more ways than one: comorbidity patterns of medically unexplained and psychiatric conditions. J Gen Intern Med 2007; 22(6): 818-21.
35. Watson S, Gallagher P, Dougall D, et al. Childhood trauma in bipolar disorder. Aust N Z J Psychiatry 2014; 48(6): 564-70.
36. Jiao J, Vincent A, Cha SS, Luedtke CA, Oh TH. Association of abuse history with symptom severity and quality of life in patients with fibromyalgia. Rheumatol Int 2015; 35(3): 547-53.
37. Nicolson NA, Davis MC, Kruszewski D, Zautra AJ. Childhood maltreatment and diurnal cortisol patterns in women with chronic pain. Psychosom Med 2010; 72(5): 471-80.
38. Fagundes CP, Glaser R, Kiecolt-Glaser JK. Stressful early life experiences and immune dysregulation across the lifespan. Brain Behav Immun 2013; 27(1): 8-12.
39. Danese A, Tan M. Childhood maltreatment and obesity: systematic review and meta-analysis. Mol Psychiatry 2014; 19(5): 544-54.
40. Dvir Y, Ford JD, Hill M, Frazier JA. Childhood maltreatment, emotional dysregulation, and psychiatric comorbidities. Harv Rev Psychiatry 2014; 22(3): 149-61.
41. Post RM, Altshuler LL, Leverich GS, et al. Role of childhood adversity in the development of medical co-morbidities associated with bipolar disorder. J Affect Disord 2013; 147(1-3): 288-94.
42. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 1999; 40(1): 57-63.
43. Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D. Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes or posttraumatic fibromyalgia syndrome? Semin Arthritis Rheum 2002; 32(1): 38-50.
44. Carta MG, Cardia C, Mannu F, et al. The high frequency of manic symptoms in fibromyalgia does influence the choice of treatment? Clin Pract Epidemiol Ment Health 2006; 2: 36.
45. Carta M, Ruggiero V, Sancassiani F, et al. The Use of Antidepressants in the Long-Term Treatment Should not Improve the Impact of Fibromyalgia on Quality of Life. Clin Pract Epidemiol Ment Health 2013; 9: 120-4.
46. Wilke WS, Gota CE, Muzina DJ. Fibromyalgia and bipolar disorder: a potential problem? Bipolar Disord 2010; 12(5): 514-20.
47. Wallace DJ, Gotto J. Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia. Semin Arthritis Rheum 2008; 37(4): 256-9.
48. Aaron LA, Bradley LA, Alarcon GS, et al. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum 1996; 39(3): 436-45.
49. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170(11): 1249-62.
50. Dell'Osso L, Bazzichi L, Consoli G, et al. Manic spectrum symptoms are correlated to the severity of pain and the health-related quality of life in patients with fibromyalgia. Clin Exp Rheumatol 2009; 27(5 Suppl 56): S57-61.
51. Alciati A, Sarzi-Puttini P, Batticciotto A, et al. Overactive lifestyle in patients with fibromyalgia as a core feature of bipolar spectrum disorder. Clin Exp Rheumatol 2012; 30(6 Suppl 74): 122-8.
52. Carta MG, Angst J. Epidemiological and clinical aspects of bipolar disorders: controversies or a common need to redefine the aims and methodological aspects of surveys. Clin Pract Epidemiol Ment Health 2005; 1(1): 4.
53. Schmechel DE, Edwards CL. Fibromyalgia, mood disorders, and intense creative energy: A1AT polymorphisms are not always silent. Neurotoxicology 2012; 33(6): 1454-72.
54. Mergener M, Becker RM, dos Santos AF, dos Santos GA, de Andrade FM. Influence of the interaction between environmental quality and T102C SNP in the HTR2A gene on fibromyalgia susceptibility. Rev Bras Reumatol 2011; 51(6): 594-602.
55. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007; 146(10): 726-34.
56. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 2000; 4(1): 5-15.
57. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 1997; 277(5328): 968-71.
58. Neugebauer V, Li W, Bird GC, Han JS. The amygdala and persistent pain. Neuroscientist 2004; 10(3): 221-34.
59. Giordano J. The neurobiology of nociceptive and antinociceptive systems. Pain Physician 2005; 8(3): 277-90.
60. Petersel DL, Dror V, Cheung R. Central amplification and fibromyalgia: disorder of pain processing. J Neurosci Res 2011; 89(1): 29-34.
61. Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chizh BA, Bushnell MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci 2007; 27(15): 4004-7.
62. Burgmer M, Gaubitz M, Konrad C, et al. Decreased gray matter volumes in the cingulo-frontal cortex and the amygdala in patients with fibromyalgia. Psychosom Med 2009; 71(5): 566-73.
63. Cagnie B, Coppieters I, Denecker S, Six J, Danneels L, Meeus M. Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. Semin Arthritis Rheum 2014; 44(1): 68-75.
64. Sawamoto N, Honda M, Okada T, et al. Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulate cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study. J Neurosci 2000; 20(19): 7438-45.
65. Luerding R, Weigand T, Bogdahn U, Schmidt-Wilcke T. Working memory performance is correlated with local brain morphology in the medial frontal and anterior cingulate cortex in fibromyalgia patients: structural correlates of pain-cognition interaction. Brain 2008; 131(Pt 12): 3222-31.
66. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004; 31(2): 364-78.
67. Staud R. Brain imaging in fibromyalgia syndrome. Clin Exp Rheumatol 2011; 29(6 Suppl 69): S109-17.
68. Cifre I, Sitges C, Fraiman D, et al. Disrupted functional connectivity of the pain network in fibromyalgia. Psychosom Med 2012; 74(1): 55-62.
69. Jorge LL, Amaro E, Jr. Brain imaging in fibromyalgia. Curr Pain Headache Rep 2012; 16(5): 388-98.
70. Harris RE, Sundgren PC, Pang Y, et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum 2008; 58(3): 903-7.
71. Aoki Y, Inokuchi R, Suwa H. Reduced N-acetylaspartate in the hippocampus in patients with fibromyalgia: a metaanalysis. Psychiatry Res 2013; 213(3): 242-8.
72. Harris RE. Elevated excitatory neurotransmitter levels in the fibromyalgia brain. Arthritis Res Ther 2010; 12(5): 141.
73. Jensen KB, Srinivasan P, Spaeth R, et al. Overlapping structural and functional brain changes in patients with longterm exposure to fibromyalgia pain. Arthritis Rheum 2013; 65(12): 3293-303.
74. Hafeman DM, Chang KD, Garrett AS, Sanders EM, Phillips ML. Effects of medication on neuroimaging findings in bipolar disorder: an updated review. Bipolar Disord 2012; 14(4): 375-410.
75. Maletic V, Raison C. Integrated neurobiology of bipolar disorder. Front Psychiatry 2014; 5: 98.
76. Strakowski SM, DelBello MP, Zimmerman ME, et al. Ventricular and periventricular structural volumes in firstversus multiple-episode bipolar disorder. Am J Psychiatry 2002; 159(11): 1841-7.
77. Oertel-Knochel V, Reuter J, Reinke B, et al. Association between age of disease-onset, cognitive performance and cortical thickness in bipolar disorders. J Affect Disord 2014; 174C: 627-35.
78. Blond BN, Fredericks CA, Blumberg HP. Functional neuroanatomy of bipolar disorder: structure, function, and connectivity in an amygdala-anterior paralimbic neural system. Bipolar Disord 2012; 14(4): 340-55.
79. Blumberg HP, Krystal JH, Bansal R, et al. Age, rapid-cycling, and pharmacotherapy effects on ventral prefrontal cortex in bipolar disorder: a cross-sectional study. Biol Psychiatry 2006; 59(7): 611-8.
80. Gruber SA, Rogowska J, Yurgelun-Todd DA. Decreased activation of the anterior cingulate in bipolar patients: an fMRI study. J Affect Disord 2004; 82(2): 191-201.
81. Strakowski SM, Adler CM, Almeida J, et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord 2012; 14(4): 313-25.
82. Townsend J, Altshuler LL. Emotion processing and regulation in bipolar disorder: a review. Bipolar Disord 2012; 14(4): 326-39.
83. Brooks JO, 3rd, Wang PW, Bonner JC, et al. Decreased prefrontal, anterior cingulate, insula, and ventral striatal metabolism in medication-free depressed outpatients with bipolar disorder. J Psychiatr Res 2009; 43(3): 181-8.
84. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7(5): 541-7.
85. Phillips ML, Swartz HA. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am J Psychiatry 2014; 171(8): 829-43.
86. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48(8): 813-29.
87. Drevets WC, Ongur D, Price JL. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol Psychiatry 1998; 3(3): 220-6, 190-1.
88. Menon V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn Sci 2011; 15(10): 483-506.
89. Hakamata Y, Iwase M, Kato T, Senda K, Inada T. The neural correlates of mindful awareness: a possible buffering effect on anxiety-related reduction in subgenual anterior cingulate cortex activity. PLoS One 2013; 8(10): e75526.
90. Blumberg HP, Fredericks C, Wang F, et al. Preliminary evidence for persistent abnormalities in amygdala volumes in adolescents and young adults with bipolar disorder. Bipolar Disord 2005; 7(6): 570-6.
91. Hulvershorn LA, Karne H, Gunn AD, et al. Neural activation during facial emotion processing in unmedicated bipolar depression, euthymia, and mania. Biol Psychiatry 2012; 71(7): 603-10.
92. Ketter TA, Kimbrell TA, George MS, et al. Effects of mood and subtype on cerebral glucose metabolism in treatmentresistant bipolar disorder. Biol Psychiatry 2001; 49(2): 97-109.
93. Vederine FE, Wessa M, Leboyer M, Houenou J. A metaanalysis of whole-brain diffusion tensor imaging studies in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(8): 1820-6.
94. Nortje G, Stein DJ, Radua J, Mataix-Cols D, Horn N. Systematic review and voxel-based meta-analysis of diffusion tensor imaging studies in bipolar disorder. J Affect Disord 2013; 150(2): 192-200.
95. Benedetti F, Absinta M, Rocca MA, et al. Tract-specific white matter structural disruption in patients with bipolar disorder. Bipolar Disord 2011; 13(4): 414-24.
96. Mahon K, Burdick KE, Szeszko PR. A role for white matter abnormalities in the pathophysiology of bipolar disorder. Neurosci Biobehav Rev 2010; 34(4): 533-54.
97. Knochel C, Stablein M, Storchak H, et al. Multimodal assessments of the hippocampal formation in schizophrenia and bipolar disorder: evidences from neurobehavioral measures and functional and structural MRI. Neuroimage Clin 2014; 6: 134-44.
98. Riva R, Mork PJ, Westgaard RH, Lundberg U. Comparison of the cortisol awakening response in women with shoulder and neck pain and women with fibromyalgia. Psychoneuroendocrinology 2012; 37(2): 299-306.
99. Tak LM, Cleare AJ, Ormel J, et al. Meta-analysis and metaregression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. Biol Psychol 2011; 87(2): 183-94.
100. Weissbecker I, Floyd A, Dedert E, Salmon P, Sephton S. Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome. Psychoneuroendocrinology 2006; 31(3): 312-24.
101. Klingmann PO, Kugler I, Steffke TS, Bellingrath S, Kudielka BM, Hellhammer DH. Sex-specific prenatal programming: a risk for fibromyalgia? Ann N Y Acad Sci 2008; 1148: 446-55.
102. Wingenfeld K, Wagner D, Schmidt I, Meinlschmidt G, Hellhammer DH, Heim C. The low-dose dexamethasone suppression test in fibromyalgia. J Psychosom Res 2007; 62(1): 85-91.
103. Wingenfeld K, Heim C, Schmidt I, Wagner D, Meinlschmidt G, Hellhammer DH. HPA axis reactivity and lymphocyte glucocorticoid sensitivity in fibromyalgia syndrome and chronic pelvic pain. Psychosom Med 2008; 70(1): 65-72.
104. Wingenfeld K, Nutzinger D, Kauth J, Hellhammer DH, Lautenbacher S. Salivary cortisol release and hypothalamic pituitary adrenal axis feedback sensitivity in fibromyalgia is associated with depression but not with pain. J Pain 2010; 11(11): 1195-202.
105. Fries E, Hesse J, Hellhammer J, Hellhammer DH. A new view on hypocortisolism. Psychoneuroendocrinology 2005; 30(10): 1010-6.
106. Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F. The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress 2007; 10(1): 13-25.
107. Lentjes EG, Griep EN, Boersma JW, Romijn FP, de Kloet ER. Glucocorticoid receptors, fibromyalgia and low back pain. Psychoneuroendocrinology 1997; 22(8): 603-14.
108. Macedo JA, Hesse J, Turner JD, Meyer J, Hellhammer DH, Muller CP. Glucocorticoid sensitivity in fibromyalgia patients: decreased expression of corticosteroid receptors and glucocorticoid-induced leucine zipper. Psychoneuroendocrinology 2008; 33(6): 799-809.
109. Bonifazi M, Suman AL, Cambiaggi C, et al. Changes in salivary cortisol and corticosteroid receptor-alpha mRNA expression following a 3-week multidisciplinary treatment program in patients with fibromyalgia. Psychoneuroendocrinology 2006; 31(9): 1076-86.
110. Geiss A, Rohleder N, Anton F. Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology 2012; 37(5): 671-84.
111. Daban C, Vieta E, Mackin P, Young AH. Hypothalamicpituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005; 28(2): 469-80.
112. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35(3): 804-17.
113. Cervantes P, Gelber S, Kin FN, Nair VN, Schwartz G. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci 2001; 26(5): 411-6.
114. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004; 184: 496-502.
115. Wieck A, Grassi-Oliveira R, do Prado CH, et al. Differential neuroendocrine and immune responses to acute psychosocial stress in women with type 1 bipolar disorder. Brain Behav Immun 2013; 34: 47-55.
116. Fries GR, Vasconcelos-Moreno MP, Gubert C, et al. Hypothalamic-pituitary-adrenal axis dysfunction and illness progression in bipolar disorder. Int J Neuropsychopharmacol 2014; 18(1). pii: pyu043.
117. Gilman SE, Ni MY, Dunn EC, et al. Contributions of the social environment to first-onset and recurrent mania. Mol Psychiatry 2015; 20(3): 329-36.
118. Goshen I, Kreisel T, Ben-Menachem-Zidon O, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008; 13(7): 717-28.
119. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A 2008; 105(2): 751-6.
120. Menzies V, Lyon DE. Integrated review of the association of cytokines with fibromyalgia and fibromyalgia core symptoms. Biol Res Nurs 2010; 11(4): 387-94.
121. Bazzichi L, Rossi A, Massimetti G, et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007; 25(2): 225-30.
122. Wang H, Moser M, Schiltenwolf M, Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia--a prospective longitudinal study over 6 months. J Rheumatol 2008; 35(7): 1366-70.
123. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001; 40(7): 743-9.
124. Cao H, Zhang YQ. Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev 2008; 32(5): 972-83.
125. Uceyler N, Valenza R, Stock M, Schedel R, Sprotte G, Sommer C. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum 2006; 54(8): 2656-64.
126. Uceyler N, Hauser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011; 12: 245.
127. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65(9): 732-41.
128. Yasui M, Yoshimura T, Takeuchi S, et al. A chronic fatigue syndrome model demonstrates mechanical allodynia and muscular hyperalgesia via spinal microglial activation. Glia 2014; 62(9): 1407-17.
129. Bierhaus A, Wolf J, Andrassy M, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A 2003; 100(4): 1920-5.
130. Stahl SM. Fibromyalgia--pathways and neurotransmitters. Hum Psychopharmacol 2009; 24 Suppl 1: S11-7.
131. Moldofsky H. The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome. CNS Spectr 2008; 13(3 Suppl 5): 22-6.
132. Werle E, Fischer HP, Muller A, Fiehn W, Eich W. Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome. J Rheumatol 2001; 28(3): 595-600.
133. Suk JH, Lee JH, Kim JM. Association between thyroid autoimmunity and fibromyalgia. Exp Clin Endocrinol Diabetes 2012; 120(7): 401-4.
134. Blankfield A. Kynurenine Pathway Pathologies: do Nicotinamide and Other Pathway Co-Factors have a Therapeutic Role in Reduction of Symptom Severity, Including Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM). Int J Tryptophan Res 2013; 6(Suppl 1): 39-45.
135. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 702-21.
136. Leonard B, Maes M. Mechanistic explanations how cellmediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012; 36(2): 764-85.
137. Iqbal R, Mughal MS, Arshad N, Arshad M. Pathophysiology and antioxidant status of patients with fibromyalgia. Rheumatol Int 2011; 31(2): 149-52.
138. La Rubia M, Rus A, Molina F, Del Moral ML. Is fibromyalgiarelated oxidative stress implicated in the decline of physical and mental health status? Clin Exp Rheumatol 2013; 31(6 Suppl 79): S121-7.
139. Bozkurt M, Caglayan M, Oktayoglu P, et al. Serum prolidase enzyme activity and oxidative status in patients with fibromyalgia. Redox Rep 2014; 19(4): 148-53.
140. Neyal M, Yimenicioglu F, Aydeniz A, et al. Plasma nitrite levels, total antioxidant status, total oxidant status, and oxidative stress index in patients with tension-type headache and fibromyalgia. Clin Neurol Neurosurg 2013; 115(6): 736-40.
141. Sendur OF, Turan Y, Tastaban E, Yenisey C, Serter M. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol Int 2009; 29(6): 629-33.
142. Akkus S, Naziroglu M, Eris S, Yalman K, Yilmaz N, Yener M. Levels of lipid peroxidation, nitric oxide, and antioxidant vitamins in plasma of patients with fibromyalgia. Cell Biochem Funct 2009; 27(4): 181-5.
143. Cordero MD, Cano-Garcia FJ, Alcocer-Gomez E, De Miguel M, Sanchez-Alcazar JA. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q(1)(0) effect on clinical improvement. PLoS One 2012; 7(4): e35677.
144. Morris G, Anderson G, Berk M, Maes M. Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol Neurobiol 2013; 48(3): 883-903.
145. Miyamae T, Seki M, Naga T, et al. Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation. Redox Rep 2013; 18(1): 12-9.
146. Cimen OB, Cimen MY, Yapici Y, Camdeviren H. Arginase, NOS activities, and clinical features in fibromyalgia patients. Pain Med 2009; 10(5): 813-8.
147. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(4): 952-5.
148. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord 2013; 150(2): 456-9.
149. Chung KH, Huang SH, Wu JY, Chen PH, Hsu JL, Tsai SY. The link between high-sensitivity C-reactive protein and orbitofrontal cortex in euthymic bipolar disorder. Neuropsychobiology 2013; 68(3): 168-73.
150. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013; 47(9): 1119-33.
151. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74(1): 15-25.
152. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6(11): 1142-51.
153. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12(4): 447-58.
154. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011; 25(6): 1206-13.
155. Barbosa IG, Rocha NP, Bauer ME, et al. Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry Clin Neurosci 2013; 263(2): 159-65.
156. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 2009; 23(8): 1079-82.
157. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 2008; 65(4): 395-407.
158. Rybakowski JK, Remlinger-Molenda A, Czech-Kucharska A, Wojcicka M, Michalak M, Losy J. Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression. J Affect Disord 2013; 146(2): 286-9.
159. Watkins CC, Sawa A, Pomper MG. Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl Psychiatry 2014; 4: e350.
160. Rege S, Hodgkinson SJ. Immune dysregulation and autoimmunity in bipolar disorder: Synthesis of the evidence and its clinical application. Aust N Z J Psychiatry 2013; 47(12): 1136-51.
161. Anderson G, Maes M. Bipolar disorder: role of immuneinflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites. Curr Psychiatry Rep 2015; 17(2): 8.
162. Brown NC, Andreazza AC, Young LT. An updated metaanalysis of oxidative stress markers in bipolar disorder. Psychiatry Res 2014; 218(1-2): 61-8.
163. Andreazza AC, Gildengers A, Rajji TK, Zuzarte PM, Mulsant BH, Young LT. Oxidative stress in older patients with bipolar disorder. Am J Geriatr Psychiatry 2015; 23(3): 314-9.
164. Soeiro-de-Souza MG, Andreazza AC, Carvalho AF, Machado-Vieira R, Young LT, Moreno RA. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol 2013; 16(7): 1505-12.
165. Kapczinski F, Dal-Pizzol F, Teixeira AL, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011; 45(2): 156-61.
166. Tsai MC, Huang TL. Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase. J Affect Disord 2015; 173: 22-6.
167. Magalhaes PV, Jansen K, Pinheiro RT, et al. Peripheral oxidative damage in early-stage mood disorders: a nested population-based case-control study. Int J Neuropsychopharmacol 2012; 15(8): 1043-50.
168. Bengesser SA, Lackner N, Birner A, et al. Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder-Gender and obesity effects. J Affect Disord 2014; 172C: 367-74.
169. Andreazza AC, Wang JF, Salmasi F, Shao L, Young LT. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem 2013; 127(4): 552-61.
170. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008; 111(2-3): 135-44.
171. Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007; 421(1): 33-6.
172. Banerjee U, Dasgupta A, Rout JK, Singh OP. Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012; 37(1): 56-61.
173. de Sousa RT, Zarate CA, Jr., Zanetti MV, et al. Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. J Psychiatr Res 2014; 50: 36-41.
174. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11(6): 851-76.
175. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995; 29(2): 141-52.
176. Maes M, Libbrecht I, Van Hunsel F, et al. The immuneinflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology 1999; 24(4): 371-83.
177. Nijs J, Meeus M, Versijpt J, et al. Brain-derived neurotrophic factor as a driving force behind neuroplasticity in neuropathic and central sensitization pain: a new therapeutic target? Expert Opin Ther Targets 2015; 19(4): 565-76.
178. Laske C, Stransky E, Eschweiler GW, et al. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res 2007; 41(7): 600-5.
179. Nugraha B, Korallus C, Gutenbrunner C. Serum level of brain-derived neurotrophic factor in fibromyalgia syndrome correlates with depression but not anxiety. Neurochem Int 2013; 62(3): 281-6.
180. Haas L, Portela LV, Bohmer AE, Oses JP, Lara DR. Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem Res 2010; 35(5): 830-4.
181. Sarchielli P, Mancini ML, Floridi A, et al. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 2007; 8(9): 737-45.
182. Zanette SA, Dussan-Sarria JA, Souza A, Deitos A, Torres IL, Caumo W. Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia. Mol Pain 2014; 10: 46.
183. Xiao Y, Russell IJ, Liu YG. A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and Creactive protein. Rheumatol Int 2012; 32(8): 2479-85.
184. Scola G, Andreazza AC. The role of neurotrophins in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2015; 56: 122-8.
185. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology 2014; 47: 199-211.
186. Cunha AB, Frey BN, Andreazza AC, et al. Serum brainderived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006; 398(3): 215-9.
187. Fernandes BS, Gama CS, Cereser KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011; 45(8): 995-1004.
188. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2015; 174: 432-40.
189. Grande I, Kapczinski F, Stertz L, et al. Peripheral brainderived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder. J Psychiatr Res 2012; 46(11): 1511-4.
190. Tang J, Xiao L, Shu C, et al. Association of the brain-derived neurotrophic factor gene and bipolar disorder with early age of onset in mainland China. Neurosci Lett 2008; 433(2): 98-102.
191. Muller DJ, de Luca V, Sicard T, King N, Strauss J, Kennedy JL. Brain-derived neurotrophic factor (BDNF) gene and rapidcycling bipolar disorder: family-based association study. Br J Psychiatry 2006; 189: 317-23.
192. Park MH, Chang KD, Hallmayer J, et al. Preliminary study of anxiety symptoms, family dysfunction, and the brain-derived neurotrophic factor (BDNF) Val66Met genotype in offspring of parents with bipolar disorder. J Psychiatr Res 2015; 61: 81-8.
193. Miller S, Hallmayer J, Wang PW, Hill SJ, Johnson SL, Ketter TA. Brain-derived neurotrophic factor val66met genotype and early life stress effects upon bipolar course. J Psychiatr Res 2013; 47(2): 252-8.
194. Aas M, Haukvik UK, Djurovic S, et al. BDNF val66met modulates the association between childhood trauma, cognitive and brain abnormalities in psychoses. Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 181-8.
195. Lotsch J, Geisslinger G. Current evidence for a modulation of nociception by human genetic polymorphisms. Pain 2007; 132(1-2): 18-22.
196. Ablin JN, Cohen H, Buskila D. Mechanisms of Disease: genetics of fibromyalgia. Nat Clin Pract Rheumatol 2006; 2(12): 671-8.
197. Mansour HA, Talkowski ME, Wood J, et al. Serotonin gene polymorphisms and bipolar I disorder: focus on the serotonin transporter. Ann Med 2005; 37(8): 590-602.
198. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007; 8(1): 67-74.
199. Vincent JB, Masellis M, Lawrence J, et al. Genetic association analysis of serotonin system genes in bipolar affective disorder. Am J Psychiatry 1999; 156(1): 136-8.
200. Murphy VE, Mynett-Johnson LA, Claffey E, Shields DC, McKeon P. No association between 5HT-2A and bipolar disorder irrespective of genomic imprinting. Am J Med Genet 2001; 105(5): 422-5.
201. Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT. Metaanalysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet 2005; 133B(1): 110-5.
202. Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999; 42(11): 2482-8.
203. Ikeda M, Iwata N, Suzuki T, et al. No association of serotonin transporter gene (SLC6A4) with schizophrenia and bipolar disorder in Japanese patients: association analysis based on linkage disequilibrium. J Neural Transm 2006; 113(7): 899-905.
204. van Ijzendoorn MH, Belsky J, Bakermans-Kranenburg MJ. Serotonin transporter genotype 5HTTLPR as a marker of differential susceptibility? A meta-analysis of child and adolescent gene-by-environment studies. Transl Psychiatry 2012; 2: e147.
205. Belsky J, Hartman S. Gene-environment interaction in evolutionary perspective: differential susceptibility to environmental influences. World Psychiatry 2014; 13(1): 87-9.
206. Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004; 9(8): 730-1.
207. Serretti A, Mandelli L, Lorenzi C, et al. Temperament and character in mood disorders: influence of DRD4, SERTPR, TPH and MAO-A polymorphisms. Neuropsychobiology 2006; 53(1): 9-16.
208. Mandelli L, Serretti A, Marino E, Pirovano A, Calati R, Colombo C. Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. Int J Neuropsychopharmacol 2007; 10(4): 437-47.
209. Soeiro-de-Souza MG, Machado-Vieira R, Soares Bio D, Do Prado CM, Moreno RA. COMT polymorphisms as predictors of cognitive dysfunction during manic and mixed episodes in bipolar I disorder. Bipolar Disord 2012; 14(5): 554-64.
210. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299(5610): 1240-3.
211. Fernandez-de-las-Penas C, Penacoba-Puente C, Cigaran-Mendez M, Diaz-Rodriguez L, Rubio-Ruiz B, Arroyo-Morales M. Has catechol-O-methyltransferase genotype (Val158Met) an influence on endocrine, sympathetic nervous and humoral immune systems in women with fibromyalgia syndrome? Clin J Pain 2014; 30(3): 199-204.
212. Anderson G, Maes M. Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol Disord Drug Targets 2014; 13(5): 817-27.
213. Robillard R, Naismith SL, Rogers NL, et al. Sleep-wake cycle and melatonin rhythms in adolescents and young adults with mood disorders: comparison of unipolar and bipolar phenotypes. Eur Psychiatry 2013; 28(7): 412-6.
214. Romo-Nava F, Alvarez-Icaza Gonzalez D, Fresan-Orellana A, et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord 2014; 16(4): 410-21.
215. Yatham LN, Vieta E, Goodwin GM, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry 2016; 208(1): 78-86.
216. Fornaro M, McCarthy MJ, De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatr Dis Treat 2013; 9: 243-51.
217. Pernambuco AP, Schetino LP, Viana RS, Carvalho LS, d'Avila Reis D. The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin Exp Rheumatol 2015; 33(1 Suppl 88): S14-9.
218. de Zanette SA, Vercelino R, Laste G, et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 2014; 15: 40.
219. Calandre EP, Slim M, Garcia-Leiva JM, Rodriguez-Lopez CM, Torres P, Rico-Villademoros F. Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: an uncontrolled, 12-week, pilot study. Pharmacopsychiatry 2014; 47(2): 67-72.
220. Bruno A, Mico U, Lorusso S, et al. Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study. J Clin Psychopharmacol 2013; 33(4): 507-11.
221. Cherniack EP, Troen BR, Florez HJ, Roos BA, Levis S. Some new food for thought: the role of vitamin D in the mental health of older adults. Curr Psychiatry Rep 2009; 11(1): 12-9.
222. Ahmadi S, Mirzaei K, Hossein-Nezhad A, Shariati G. Vitamin D receptor FokI genotype may modify the susceptibility to schizophrenia and bipolar mood disorder by regulation of dopamine D1 receptor gene expression. Minerva Med 2012; 103(5): 383-91.
223. Sanders KM, Stuart AL, Williamson EJ, et al. Annual highdose vitamin D3 and mental well-being: randomised controlled trial. Br J Psychiatry 2011; 198(5): 357-64.
224. von Kanel R, Muller-Hartmannsgruber V, Kokinogenis G, Egloff N. Vitamin D and central hypersensitivity in patients with chronic pain. Pain Med 2014; 15(9): 1609-18.
225. Okumus M, Koybasi M, Tuncay F, et al. Fibromyalgia syndrome: is it related to vitamin D deficiency in premenopausal female patients? Pain Manag Nurs 2013; 14(4): e156-63.
226. McBeth J, Pye SR, O'Neill TW, et al. Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study. Ann Rheum Dis 2010; 69(8): 1448-52.
227. Heidari B, Shirvani JS, Firouzjahi A, Heidari P, Hajian-Tilaki KO. Association between nonspecific skeletal pain and vitamin D deficiency. Int J Rheum Dis 2010; 13(4): 340-6.
228. Wepner F, Scheuer R, Schuetz-Wieser B, et al. Effects of vitamin D on patients with fibromyalgia syndrome: a randomized placebo-controlled trial. Pain 2014; 155(2): 261-8.
229. Ubbenhorst A, Striebich S, Lang F, Lang UE. Exploring the relationship between vitamin D and basic personality traits. Psychopharmacology (Berl) 2011; 215(4): 733-7.
230. Kuningas M, Mooijaart SP, Jolles J, Slagboom PE, Westendorp RG, van Heemst D. VDR gene variants associate with cognitive function and depressive symptoms in old age. Neurobiol Aging 2009; 30(3): 466-73.
231. Morris G, Berk M. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med 2015; 13: 68.
232. Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int J Clin Exp Med 2012; 5(3): 208-20.
233. Castro-Marrero J, Cordero MD, Saez-Francas N, et al. Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia? Antioxid Redox Signal 2013; 19(15): 1855-60.
234. Smits B, van den Heuvel L, Knoop H, et al. Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome. Mitochondrion 2011; 11(5): 735-8.
235. Behan WM, More IA, Behan PO. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991; 83(1): 61-5.
236. Caliyurt O, Altiay G. Resting energy expenditure in manic episode. Bipolar Disord 2009; 11(1): 102-6.
237. Scola G, Kim HK, Young LT, Andreazza AC. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol Psychiatry 2013; 73(2): e4-5.
238. Callaly E, Walder K, Morris G, Maes M, Debnath M, Berk M. Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev Med Chem 2015; 15(5): 355-65.
239. Park S, Cho MJ, Seong S, et al. Psychiatric morbidities, sleep disturbances, suicidality, and quality-of-life in a community population with medically unexplained pain in Korea. Psychiatry Res 2012; 198(3): 509-15.
240. Trinanes Y, Gonzalez-Villar A, Gomez-Perretta C, Carrillode-la-Pena MT. Suicidality in Chronic Pain: Predictors of Suicidal Ideation in Fibromyalgia. Pain Pract 2015; 15(4): 323-32.
241. Carvalho AF, Takwoingi Y, Sales PM, et al. Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies. J Affect Disord 2014; 172C: 337-46.
242. Subramaniam M, Abdin E, Vaingankar JA, Chong SA. Prevalence, correlates, comorbidity and severity of bipolar disorder: results from the Singapore Mental Health Study. J Affect Disord 2013; 146(2): 189-96.
243. Smith DJ, Martin D, McLean G, Langan J, Guthrie B, Mercer SW. Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study. BMC Med 2013; 11: 263.
244. Cordero MD, Alcocer-Gomez E, Cano-Garcia FJ, et al. Clinical symptoms in fibromyalgia are associated to overweight and lipid profile. Rheumatol Int 2014; 34(3): 419-22.